AU2004289223B2 - Once daily dosage forms of trospium - Google Patents
Once daily dosage forms of trospium Download PDFInfo
- Publication number
- AU2004289223B2 AU2004289223B2 AU2004289223A AU2004289223A AU2004289223B2 AU 2004289223 B2 AU2004289223 B2 AU 2004289223B2 AU 2004289223 A AU2004289223 A AU 2004289223A AU 2004289223 A AU2004289223 A AU 2004289223A AU 2004289223 B2 AU2004289223 B2 AU 2004289223B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- trospium
- trospium chloride
- release
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 title claims abstract description 72
- 229960001491 trospium Drugs 0.000 title claims abstract description 61
- 239000002552 dosage form Substances 0.000 title description 21
- 230000036765 blood level Effects 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 claims description 151
- 229960001530 trospium chloride Drugs 0.000 claims description 151
- 239000000203 mixture Substances 0.000 claims description 122
- 239000008188 pellet Substances 0.000 claims description 108
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 90
- 230000003111 delayed effect Effects 0.000 claims description 57
- 238000000576 coating method Methods 0.000 claims description 51
- 238000013265 extended release Methods 0.000 claims description 48
- 239000011248 coating agent Substances 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 36
- 238000009472 formulation Methods 0.000 claims description 33
- 239000006185 dispersion Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 25
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000000454 talc Substances 0.000 claims description 16
- 229910052623 talc Inorganic materials 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- -1 sachet Substances 0.000 claims description 13
- 235000012222 talc Nutrition 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 9
- 239000001069 triethyl citrate Substances 0.000 claims description 8
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000013769 triethyl citrate Nutrition 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 210000001072 colon Anatomy 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 6
- 210000000936 intestine Anatomy 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 206010013781 dry mouth Diseases 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 238000013103 analytical ultracentrifugation Methods 0.000 claims 1
- 230000003467 diminishing effect Effects 0.000 claims 1
- 239000007942 layered tablet Substances 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 34
- 229920003134 Eudragit® polymer Polymers 0.000 description 27
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 22
- 238000004090 dissolution Methods 0.000 description 21
- 230000036470 plasma concentration Effects 0.000 description 19
- 206010020853 Hypertonic bladder Diseases 0.000 description 17
- 239000000463 material Substances 0.000 description 15
- 239000008363 phosphate buffer Substances 0.000 description 15
- 238000013270 controlled release Methods 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 10
- 206010046494 urge incontinence Diseases 0.000 description 10
- 206010036018 Pollakiuria Diseases 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 206010029446 nocturia Diseases 0.000 description 8
- 208000022934 urinary frequency Diseases 0.000 description 8
- 230000036318 urination frequency Effects 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229920003091 Methocel™ Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000008116 calcium stearate Substances 0.000 description 4
- 235000013539 calcium stearate Nutrition 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012735 once-a-day formulation Substances 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- 206010069632 Bladder dysfunction Diseases 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920003110 Primojel Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940112041 peripherally acting muscle relaxants other quaternary ammonium compound in atc Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 239000004859 Copal Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 241000782205 Guibourtia conjugata Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- AEMQUICCWRPKDB-UHFFFAOYSA-N acetic acid;cyclohexane-1,2-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1CCCCC1C(O)=O AEMQUICCWRPKDB-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- HOOSGZJRQIVJSZ-NNBUQUNQSA-N clidinium Chemical compound C1([C@H]2CC[N@+](CC2)(C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HOOSGZJRQIVJSZ-NNBUQUNQSA-N 0.000 description 1
- 229960003154 clidinium Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009500 colour coating Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical compound C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 description 1
- 229960002236 emepronium Drugs 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51719803P | 2003-11-04 | 2003-11-04 | |
| US52396803P | 2003-11-21 | 2003-11-21 | |
| PCT/US2004/036394 WO2005046684A1 (en) | 2003-11-04 | 2004-11-04 | Once daily dosage forms of trospium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004289223A1 AU2004289223A1 (en) | 2005-05-26 |
| AU2004289223B2 true AU2004289223B2 (en) | 2009-11-05 |
Family
ID=34594857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004289223A Ceased AU2004289223B2 (en) | 2003-11-04 | 2004-11-04 | Once daily dosage forms of trospium |
Country Status (11)
| Country | Link |
|---|---|
| US (12) | US7410978B2 (OSRAM) |
| EP (2) | EP2210605B1 (OSRAM) |
| JP (2) | JP5610663B2 (OSRAM) |
| AT (1) | ATE493981T1 (OSRAM) |
| AU (1) | AU2004289223B2 (OSRAM) |
| CA (1) | CA2537103C (OSRAM) |
| DE (1) | DE602004030931D1 (OSRAM) |
| DK (1) | DK2210605T3 (OSRAM) |
| ES (1) | ES2359375T3 (OSRAM) |
| PT (1) | PT2210605T (OSRAM) |
| WO (1) | WO2005046684A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005046663A1 (en) | 2003-11-04 | 2005-05-26 | Shire Laboratories, Inc. | Compositions of quaternary ammonium containing bioavailability enhancers |
| EP2210605B1 (en) * | 2003-11-04 | 2017-03-01 | TCD Royalty Sub, LLC | Once daily dosage forms of trospium |
| US20070134315A1 (en) * | 2005-12-08 | 2007-06-14 | Viera Michael L | Orally administrable extended release pellet and tablet formulations of a highly water soluble compound |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| EP1880718B1 (de) * | 2006-07-10 | 2011-09-21 | Dr. R. Pfleger Chemische Fabrik GmbH | Pharmazeutische Zubereitung für die orale Verabreichung mit gesteuerter Wirkstofffreisetzung im Dünndarm und Verfahren zu ihrer Herstellung |
| US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| WO2008061226A2 (en) | 2006-11-17 | 2008-05-22 | Supernus Pharmaceuticals Inc. | Sustained-release formulations of topiramate |
| EP2061431B1 (en) * | 2006-12-04 | 2013-04-24 | Supernus Pharmaceuticals, Inc. | Enhanced immediate release formulations of topiramate |
| WO2009130712A2 (en) * | 2008-04-22 | 2009-10-29 | Lupin Limited | Controlled release pharmaceutical compositions of trospium |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| DK3061821T3 (da) * | 2009-07-22 | 2019-08-26 | PureTech Health LLC | Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering |
| SG174658A1 (en) | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| WO2011159824A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | Composition and method for treating overactive bladder |
| ES2575860T3 (es) | 2010-07-09 | 2016-07-01 | Bhv Pharma, Inc. | Sistema de administración de liberación inmediata/retardada de combinación para productos farmacéuticos de semivida corta que incluyen remogliflozina |
| EP2706998A1 (en) * | 2011-05-10 | 2014-03-19 | Theravida, Inc. | Combinations of trospium and salivary stimulants for the treatment of overactive bladder |
| EP3167885A1 (en) | 2011-05-10 | 2017-05-17 | TheraVida, Inc. | Combinations of solifenacin and pilocarpine for the treatment of overactive bladder |
| EA028224B1 (ru) * | 2012-03-02 | 2017-10-31 | Роудс Фармасьютикалз Л.П. | Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения |
| WO2013139292A1 (zh) * | 2012-03-23 | 2013-09-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种含辛弗林和托吡酯的联合产品 |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| MX358211B (es) * | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. |
| US8962020B2 (en) * | 2012-07-26 | 2015-02-24 | Glycadia Inc. | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
| US10751287B2 (en) * | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| CN104739808B (zh) * | 2015-02-13 | 2017-09-22 | 舒泰神（北京）生物制药股份有限公司 | 一种曲司氯铵双释放胶囊及其制备方法 |
| RU2718906C2 (ru) | 2016-01-20 | 2020-04-15 | Теравида, Инк. | Способы и композиции для лечения гипергидроза |
| IL295341B2 (en) | 2018-09-28 | 2025-01-01 | Karuna Therapeutics Inc | Compositions and methods for treating diseases improved by activating muscarinic receptors |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1194422B (de) * | 1963-03-05 | 1965-06-10 | Robert Pfleger Chem Fab Dr | Verfahren zur Herstellung von Azoniaspironortropanderivaten |
| US5998460A (en) * | 1991-09-26 | 1999-12-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Phenylcarbamates of (-)-eseroline, (-)-N1-noreseroline and (-)-N1-benzylnoreseroline: selective inhibitors of acetyl and butyrylcholinesterase, pharmaceutical compositions and method of use thereof |
| WO2004000280A1 (en) * | 2002-04-29 | 2003-12-31 | Shire Laboraties, Inc. | Pharmaceutical formulations with improved bioavailability |
| WO2004062577A2 (en) * | 2003-01-03 | 2004-07-29 | Shire Laboratories Inc. | Two or more enteric materials to regulate drug release |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2899357A (en) * | 1959-08-11 | Oral pharmaceutical composition for | ||
| US518777A (en) * | 1894-04-24 | Bicycle | ||
| US652837A (en) * | 1899-11-17 | 1900-07-03 | Daniel Mcnamara | Wheel for vehicles. |
| US2095282A (en) | 1935-03-15 | 1937-10-12 | Standard Oil Co | Capillary viscometer |
| US2956926A (en) | 1958-09-23 | 1960-10-18 | American Cyanamid Co | Coated citric acid particles |
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| US4259314A (en) | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| DE3237575A1 (de) | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| EP0193056B1 (de) | 1985-02-23 | 1989-06-07 | ASTA Pharma Aktiengesellschaft | Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US4713243A (en) | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
| JP2528652B2 (ja) | 1987-03-30 | 1996-08-28 | エスエス製薬株式会社 | 持効性セフラジン製剤 |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5279660A (en) | 1988-05-24 | 1994-01-18 | Berol Nobel Stenungsund Ab | Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system |
| US5520932A (en) | 1988-06-24 | 1996-05-28 | The Upjohn Company | Fine-milled colestipol hydrochloride |
| US4970081A (en) * | 1989-01-03 | 1990-11-13 | Sterling Drug Inc. | Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith |
| US5330766A (en) | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5372823A (en) | 1989-03-16 | 1994-12-13 | Bristol-Myers Squibb Company | Direct compression cholestyramine tablet and solvent-free coating thereof |
| US5179660A (en) * | 1989-05-15 | 1993-01-12 | International Business Machines Incorporated | System for reducing communications overhead in distributed database transactions by serializing in order related requests into single transmission message and receiving transmission response |
| US5158777A (en) | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| EP0481038B1 (en) * | 1990-04-16 | 2002-10-02 | The Trustees Of The University Of Pennsylvania | Saccharide compositions, methods and apparatus for their synthesis |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5686094A (en) | 1991-04-01 | 1997-11-11 | Theratech, Inc. | Controlled release formulations for the treatment of xerostomia |
| US5095282A (en) * | 1990-08-23 | 1992-03-10 | Nvision, Inc. | Differential amplifier apparatus |
| US5203203A (en) | 1990-10-10 | 1993-04-20 | Bryan William L | Viscometer for in situ monitoring |
| US5326570A (en) | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| CA2130487A1 (en) * | 1992-02-18 | 1993-08-19 | Kouichi Nakamichi | Fast soluble tablet |
| US5405648A (en) | 1993-05-10 | 1995-04-11 | Hermann; Paul F. | Coating particulate material with a polymer film |
| WO1995005809A1 (en) * | 1993-08-20 | 1995-03-02 | Nippon Shinyaku Co., Ltd. | Gastric remaining preparation, swollen molding, and production process |
| EP0716597A1 (en) * | 1993-08-30 | 1996-06-19 | Warner-Lambert Company | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
| US5399359A (en) | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
| US6077533A (en) * | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
| US5520832A (en) * | 1994-10-28 | 1996-05-28 | Exxon Research And Engineering Company | Tractor hydraulic fluid with wide temperature range (Law180) |
| JPH08157392A (ja) | 1994-12-01 | 1996-06-18 | Kanegafuchi Chem Ind Co Ltd | 放出制御型製剤 |
| US5582838A (en) | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
| FI98343C (fi) | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
| US6124355A (en) * | 1995-05-22 | 2000-09-26 | Guittard; George V. | Oxybutynin therapy |
| US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| US5879712A (en) | 1995-06-07 | 1999-03-09 | Sri International | Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced |
| US5779661A (en) * | 1995-12-11 | 1998-07-14 | Physion, S.R.L. | Method of treating dysfunctional bladder syndromes by electromotive drug administration |
| JPH09188617A (ja) * | 1996-01-08 | 1997-07-22 | Pola Chem Ind Inc | 徐放性医薬組成物 |
| JP3929522B2 (ja) * | 1996-03-14 | 2007-06-13 | 塩野義製薬株式会社 | 難水溶性薬物の徐放性製剤 |
| US6156340A (en) | 1996-03-29 | 2000-12-05 | Duquesne University Of The Holy Ghost | Orally administrable time release drug containing products |
| US20030064108A1 (en) | 1996-04-23 | 2003-04-03 | Stefan Lukas | Taste masked pharmaceutical compositions |
| US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
| JPH09315969A (ja) | 1996-05-24 | 1997-12-09 | Taiyo Yakuhin Kogyo Kk | イブジラスト含有徐放性医薬品組成物及びその製造方法 |
| US6063808A (en) | 1996-07-01 | 2000-05-16 | Sepracor Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate |
| US5959196A (en) | 1996-09-10 | 1999-09-28 | Norcross Corporation | In-line viscometer |
| US20010003588A1 (en) | 1996-09-12 | 2001-06-14 | Smithkline Beecham Corporation | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| ES2125696T3 (es) * | 1996-11-27 | 1999-03-01 | Pfleger R Chem Fab | Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales. |
| US5973389A (en) * | 1997-04-22 | 1999-10-26 | International Business Machines Corporation | Semiconductor chip carrier assembly |
| US6141624A (en) * | 1997-05-13 | 2000-10-31 | International Remote Imaging Systems | Fluid sample for analysis controlled by total fluid volume and by total particle counts |
| EP0914098B1 (en) | 1997-05-30 | 2003-10-01 | Osmotica Corp. | Multi-layered osmotic device |
| US6141625A (en) | 1997-06-09 | 2000-10-31 | Dickey-John Corporation | Viscometer module with crystal resonator-type sensor |
| DE19724696A1 (de) | 1997-06-12 | 1998-12-24 | Hexal Ag | Pharmazeutische Zubereitung mit drei Pelletarten |
| US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
| US6337091B1 (en) | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
| CO5070568A1 (es) | 1998-05-22 | 2001-08-28 | Eurand Internatrional Spa | Proceso de aplicacion de capas y aparato para efectuarlo |
| KR100501022B1 (ko) | 1998-07-28 | 2005-07-18 | 다나베 세이야꾸 가부시키가이샤 | 장내 적소 방출형 제제 |
| JP2000103732A (ja) * | 1998-07-28 | 2000-04-11 | Tanabe Seiyaku Co Ltd | 腸内適所放出型製剤 |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| WO2000012069A1 (en) | 1998-08-27 | 2000-03-09 | Pharmacia & Upjohn Ab | Therapeutic formulation for administering tolterodine with controlled release |
| US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| AU6228799A (en) | 1998-10-26 | 2000-05-15 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
| US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| DK1146862T3 (da) | 1999-01-29 | 2003-07-21 | Disphar Int Bv | Farmaceutiske sammensætninger |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6576619B2 (en) | 1999-05-24 | 2003-06-10 | Cv Therapeutics, Inc. | Orally active A1 adenosine receptor agonists |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| ATE258417T1 (de) | 1999-07-02 | 2004-02-15 | Cognis Iberia Sl | Mikrokapseln - i |
| JP2003508420A (ja) | 1999-09-02 | 2003-03-04 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | 経口投与に適した、制御された放出の経口用量 |
| PT1207860E (pt) | 1999-09-02 | 2008-01-24 | Nostrum Pharmaceuticals Inc | Formulação de peletes de libertação controlada |
| US20020004065A1 (en) | 2000-01-20 | 2002-01-10 | David Kanios | Compositions and methods to effect the release profile in the transdermal administration of active agents |
| KR100574213B1 (ko) | 2000-01-27 | 2006-04-27 | 다나베 세이야꾸 가부시키가이샤 | 서방성 제제 및 그의 제조 방법 |
| CN1396829A (zh) | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| EP1272181A2 (en) | 2000-04-13 | 2003-01-08 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
| US6350471B1 (en) | 2000-05-31 | 2002-02-26 | Pharma Pass Llc | Tablet comprising a delayed release coating |
| ES2325057T3 (es) | 2000-08-31 | 2009-08-25 | Jagotec Ag | Particulas molturadas. |
| US6620439B1 (en) * | 2000-10-03 | 2003-09-16 | Atul M. Mehta | Chrono delivery formulations and method of use thereof |
| ES2298236T3 (es) | 2001-01-31 | 2008-05-16 | Evonik Rohm Gmbh | Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente. |
| ATE357216T1 (de) | 2001-02-22 | 2007-04-15 | Jagotec Ag | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen |
| AUPR752201A0 (en) * | 2001-09-07 | 2001-09-27 | Schefenacker Vision Systems Australia Pty Ltd | Powered telescoping trailer tow mirror |
| MXPA04003865A (es) | 2001-10-26 | 2004-07-08 | Upjohn Co | Compuestos de amonio cuaternario y sus usos como agentes antimuscarinicos. |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US6682759B2 (en) * | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
| US7588825B2 (en) | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US6974820B2 (en) | 2002-11-06 | 2005-12-13 | Bridge Pharma, Inc. | Methods for treating urinary incontinence and other disorders using trospium |
| US20040138634A1 (en) | 2003-01-10 | 2004-07-15 | Litvay John D. | Absorbent article having improved softness |
| PL377995A1 (pl) | 2003-01-22 | 2006-02-20 | Pfizer Health Ab | Zmniejszona dawka tolterodyny i innych środków przeciwmuskarynowych do leczenia zaburzeń układu moczowego |
| US20040202693A1 (en) | 2003-04-14 | 2004-10-14 | Rong-Kun Chang | Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem |
| US20050009862A1 (en) | 2003-04-25 | 2005-01-13 | Sabounjian Luann | Method for promoting uninterrupted sleep by administration of trospium chloride |
| US6772801B1 (en) | 2003-05-14 | 2004-08-10 | Shire Laboratories, Inc. | Fluidization of particles for encapsulation in oral dosage pharmaceutical products |
| EP2210605B1 (en) * | 2003-11-04 | 2017-03-01 | TCD Royalty Sub, LLC | Once daily dosage forms of trospium |
| EP1788939A4 (en) * | 2004-09-08 | 2009-11-25 | Univ Ramot | CONTRAST AND MRI METHOD |
| JP2006146117A (ja) * | 2004-10-20 | 2006-06-08 | Brother Ind Ltd | 画像形成装置 |
-
2004
- 2004-11-04 EP EP10001664.1A patent/EP2210605B1/en not_active Expired - Lifetime
- 2004-11-04 PT PT100016641T patent/PT2210605T/pt unknown
- 2004-11-04 WO PCT/US2004/036394 patent/WO2005046684A1/en not_active Ceased
- 2004-11-04 ES ES04800569T patent/ES2359375T3/es not_active Expired - Lifetime
- 2004-11-04 AT AT04800569T patent/ATE493981T1/de not_active IP Right Cessation
- 2004-11-04 AU AU2004289223A patent/AU2004289223B2/en not_active Ceased
- 2004-11-04 EP EP04800569A patent/EP1680110B1/en not_active Expired - Lifetime
- 2004-11-04 CA CA002537103A patent/CA2537103C/en not_active Expired - Fee Related
- 2004-11-04 US US10/980,818 patent/US7410978B2/en not_active Expired - Fee Related
- 2004-11-04 DE DE602004030931T patent/DE602004030931D1/de not_active Expired - Lifetime
- 2004-11-04 DK DK10001664.1T patent/DK2210605T3/en active
- 2004-11-04 JP JP2006538425A patent/JP5610663B2/ja not_active Expired - Fee Related
-
2007
- 2007-08-17 US US11/889,985 patent/US7763635B2/en not_active Expired - Fee Related
- 2007-08-17 US US11/889,964 patent/US7759359B2/en not_active Expired - Fee Related
- 2007-08-17 US US11/889,963 patent/US7781449B2/en not_active Expired - Fee Related
- 2007-08-17 US US11/889,962 patent/US7781448B2/en not_active Expired - Fee Related
-
2010
- 2010-05-12 US US12/778,791 patent/US20100221356A1/en not_active Abandoned
- 2010-05-12 US US12/778,664 patent/US20100221355A1/en not_active Abandoned
- 2010-05-12 US US12/778,593 patent/US20100221352A1/en not_active Abandoned
- 2010-05-12 US US12/778,604 patent/US20100221353A1/en not_active Abandoned
- 2010-05-12 US US12/778,609 patent/US20100221354A1/en not_active Abandoned
- 2010-05-12 US US12/778,568 patent/US20100222375A1/en not_active Abandoned
-
2012
- 2012-05-01 JP JP2012104795A patent/JP5783489B2/ja not_active Expired - Fee Related
- 2012-09-19 US US13/622,804 patent/US20130089607A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1194422B (de) * | 1963-03-05 | 1965-06-10 | Robert Pfleger Chem Fab Dr | Verfahren zur Herstellung von Azoniaspironortropanderivaten |
| US5998460A (en) * | 1991-09-26 | 1999-12-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Phenylcarbamates of (-)-eseroline, (-)-N1-noreseroline and (-)-N1-benzylnoreseroline: selective inhibitors of acetyl and butyrylcholinesterase, pharmaceutical compositions and method of use thereof |
| WO2004000280A1 (en) * | 2002-04-29 | 2003-12-31 | Shire Laboraties, Inc. | Pharmaceutical formulations with improved bioavailability |
| WO2004062577A2 (en) * | 2003-01-03 | 2004-07-29 | Shire Laboratories Inc. | Two or more enteric materials to regulate drug release |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7781449B2 (en) | Trospium chloride treatment method | |
| EP1123087B1 (en) | Oral pulsed dose drug delivery system | |
| US9040086B2 (en) | Timed, sustained release systems for propranolol | |
| PL200816B1 (pl) | Powleczony rdzeń o opóźnionym uwalnianiu dający impuls czasowy uwalniania i farmaceutyczna postać dawkowana | |
| CA2303973C (en) | Prolonged release formulation of carbamazepine | |
| CA2380333A1 (en) | Pharmaceutical formulations | |
| AU2018286535B2 (en) | Delayed sustained release pharmaceutical compositions | |
| KR20070044911A (ko) | 염산 탐스로신 함유 방출조절 제제 | |
| HK1088547B (en) | Once daily dosage forms of trospium | |
| MXPA06004017A (es) | Formas de dosis una vez al dia de trospio | |
| JP2003507416A (ja) | 医薬製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: SUPERNUS PHARMACEUTICALS, INC Free format text: FORMER APPLICANT(S): SHIRE LABORATORIES, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |